Mike Doustdar

Thanks very much for having me, Katie.

As they say, Christmas comes early, so I'm super excited, of course, to be here announcing the Wegovy pill.

As you say, this is really going to be super exciting for the millions of patients that have been waiting for

to get their hands on a GLP-1 pill.

And for the first time, we are having a pill that has an efficacy of some 17% if you take the pill regularly, and one in three people are going to actually reduce up to 20% weight loss.

I think that data speaks for itself, and we are super excited, of course, to be the first to the market, and we're going to go all in trying to make this a huge success.

Yeah, so as I mentioned, there are no other phase three trials of oral GOP1 that has shown this level efficacy.

This means that for the first time ever, people do not have to compromise between either taking an efficacious injection or a convenient pill.

For the first time ever, you have the same efficacy of 17% in injection

or a pill.

You can take it on a daily basis as a pill or a weekly injection.

And that, I think, is the key selling point with Vigovipil.

We also have more than 10 years of, of course, experience with regards to safety data and what have you.

That's why it's called the Vigovipil, which means that this pill is not only going to reduce your weight, it also has protection for your cardiovascular systems.

So this is a phenomenal pill, second to none, I would say.

and we are very ready to compete with it.

The quick answer is yes.

We're going all in.

We're, of course, going to sell this through our own websites, Novocare Pharmacy, as well as all of our partners, Beard Row, LifeMD, Costco, Weight Watchers.

Everyone that you can imagine is going to start launching this at the same time on the day of the launch.